Clarus Ventures
VC Fund
Cambridge, United States
Clarus Ventures is a life sciences venture capital firm founded by a team of accomplished investment professionals with extensive and complementary industry backgrounds which have enabled them to establish a long history of success in creating value. Their deep relationships with world thought leaders and decision makers allow this team toidentify unique investment opportunities and shepherd them to maturity. Clarus augments its core expertise of investing in biopharmaceuticals and medical technology companies with the deep and diverse expertise of the team in research and development, commercialization, business development and operations management at the global level. Clarus has $1.2 billion of assets under management across two lifesciences dedicated funds
- Total investments:
- 72
- Last investment:
- Lead investor:
- 39%
Last updated:
For AI agents: llms.txt
Industries Clarus Ventures invests in
Stages Clarus Ventures invests in
Countries Clarus Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Nicholas J. Simon
|
|||
Christine Esguerra
|
|||
|
Elsa Gelin
|
|||
Emmett Cunningham
|
|||
|
Kayla Seaman
|
Investment Focus
Industry
- Biotechnology 31 (43%)
- Health Care 28 (39%)
- Pharmaceutical 11 (15%)
- Medical 10 (14%)
- Medical Device 8 (11%)
Stage
- Series B 17 (24%)
- Series A 14 (19%)
- Funding Round 13 (18%)
- Series C 5 (7%)
- Series D 5 (7%)
Country
- United States 31 (43%)
- United Kingdom 3 (4%)
- Switzerland 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Nicholas J. Simon
Managing Director
|
Managing Director | Total investments: 8 | Find email | |
|
Christine Esguerra
Executive Assistant
|
Executive Assistant | Total investments: 0 | Find email | |
|
Elsa Gelin
Controller
|
Controller | Total investments: 0 | Find email | |
|
Emmett Cunningham
Partner & Managing Director
|
Partner & Managing Director | Total investments: 2 | Find email | |
|
Kayla Seaman
Executive Assistant
|
Executive Assistant | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Galera Therapeutics
|
Galera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation therapy is used in patients with cancer. Galera’s lead product candidate is GC4419, a highly selective and potent smallmolecule superoxide dismutase enzyme mimetic that rapidly converts superoxide to hydrogen peroxide and oxygen. GC4419 achieved positive results in a Phase 2b clinical trial, which demonstrated its ability to reduce the incidence and duration of radiation-induced severe oral mucositis in patients with head and neck cancer, it's lead indication. The U.S. Food and Drug Administration granted Fast Track and Breakthrough Therapy designations to GC4419.The company was established in 2009 and is headquartered in Malvern, Pennsylvania, United States. | $70M / Series C / Sep 19, 2018 | |
Avrobio
|
Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.The catalyst for creating Avrobio is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies. The patient’s own cells can be effectively modified to deliver novel genes to cure seriousdebilitating disease.Avrobio was founded by industry leaders with unmatched scientific, business, and manufacturing expertise in the field of cell and gene therapy. | $60M / Series B / Feb 01, 2018 | |
Forty Seven
|
Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells commandeer toavoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma. | $75M / Series B / Oct 17, 2017 | |
Gritstone bio
|
Gritstone Oncology is a clinical-stage biotech company developing tumor-specific cancer immunotherapies to fight multiple cancer types. Its approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy tumor cells by targeting tumor-specific neoantigens. GritstoneOncology is headquartered in Emeryville, California, with key functions located in Cambridge, Massachusetts, and Pleasanton, California. It was founded in August 2015 and is listed on the Nasdaq Global Select Market under the ticker symbol GRTS. | $93M / Series B / Sep 07, 2017 | |
PATH
|
PATH is an international nonprofit organization that transforms global health through innovation. They take an entrepreneurial approach to developing and delivering high-impact, low-cost solutions, from lifesaving vaccines and devices to collaborative programs with communities. Through our work in more than 70 countries, PATH and our partnersempower people to achieve their full potential. | $25M / Feb 01, 2017 | |
Cleave Therapeutics
|
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer. | $37M / Series B / Aug 17, 2016 | |
|
Avrobio
|
Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.The catalyst for creating Avrobio is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies. The patient’s own cells can be effectively modified to deliver novel genes to cure seriousdebilitating disease.Avrobio was founded by industry leaders with unmatched scientific, business, and manufacturing expertise in the field of cell and gene therapy. | $25M / Series A / Aug 02, 2016 | |
Annexon Biosciences
|
Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes,both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue. | $44M / Series B / Jun 23, 2016 | |
Flowonix
|
Flowonix is a medical device company dedicated to helping those who suffer from chronic disorders. Their team has decades of experience developing unique and reliable medical devices to improve lifestyles. Using one of a kind technology, Flowonix has developed an implantable drug pump designed to deliver therapeutic drugs into the spine to relievea variety of chronic disorders and help patients return to normal lives. | $5M / Debt Financing / Jun 02, 2016 | |
GrayBug
|
GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and itsown therapeutic products for major ocular disease indications including wet AMD and Glaucoma.The company was founded in 2011 and headquartered in Baltimore, Maryland. | Series B / May 02, 2016 | |
| See all 72 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Clarus Ventures invest in?
Clarus Ventures invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 72 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Clarus Ventures?
Public channels for Clarus Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Clarus Ventures?
The team at Clarus Ventures includes Nicholas J. Simon (Managing Director), Christine Esguerra (Executive Assistant) and Elsa Gelin (Controller), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
